News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ZOLINZA (vorinostat) in Combination with Bortezomib Demonstrated Clinical Activity
December 10, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Alzheimer’s disease
AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance
July 15, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time
July 15, 2026
·
1 min read
·
Nick Paul Taylor
Psychedelics
Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed
July 14, 2026
·
3 min read
·
Michael Gibney
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
July 13, 2026
·
4 min read
·
Heather McKenzie
